Nicolaos Athienites, MD
Nephrology · Brockton, MANPI 1902804107
Payments from drug & device makers
Across 932 payments — averaging $315.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$106K
- AstraZeneca$95K
- Mallinckrodt Enterprises LLC$38K
- ANI Pharmaceuticals, Inc.$20K
- Travere Therapeutics, Inc.$15K
- Mallinckrodt Hospital Products Inc.$11K
- plus $9K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 189 | $105,919 |
| AstraZeneca(2 entities) | 148 | $95,128 |
| Mallinckrodt Enterprises LLC | 29 | $38,193 |
| ANI Pharmaceuticals, Inc. | 125 | $19,935 |
| Travere Therapeutics, Inc. | 63 | $15,042 |
| Mallinckrodt Hospital Products Inc. | 35 | $11,293 |
| Vifor Pharma, Inc. | 73 | $1,762 |
| Fresenius USA Marketing, Inc. | 15 | $1,254 |
| Otsuka America Pharmaceutical, Inc. | 43 | $886 |
| OPKO Pharmaceuticals, LLC | 42 | $785 |
| Novartis | 23 | $616 |
| Bayer | 30 | $582 |
| Daiichi Sankyo Inc. | 25 | $492 |
| GSK | 25 | $428 |
| Akebia Therapeutics Inc | 10 | $414 |
| Alnylam Pharmaceuticals Inc. | 12 | $260 |
| Calliditas Therapeutics US Inc. | 12 | $251 |
| Ardelyx, Inc. | 7 | $181 |
| Novo Nordisk | 6 | $119 |
| Aurinia Pharma U.S., Inc. | 4 | $110 |
| Boehringer Ingelheim | 4 | $96 |
| Scpharmaceuticals Inc. | 3 | $60 |
| Boston Scientific | 1 | $49 |
| Shield Therapeutics Inc | 2 | $45 |
| Recor Medical Inc | 2 | $44 |
| Sanofi | 2 | $38 |
| Cormedix Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
How this compares
$294,032 in reported general payments places this provider in the 90th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Brockton
- David FriedmanBoston$24.5M
- Martin PollakBoston$24.4M
- Dennis AusielloBoston$4.6M
- Subbian KarumanchiBoston$4.1M
- David ShihNorth Dartmouth$2.3M
- Anil ChandrakerWorcester$1.5M
- Jamil AzziBoston$1.4M
- Finnian McCauslandBoston$1.2M
- Meghan SiseBoston$1.2M
- Andrew AllegrettiBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.